Keywords: celgene, revlimid, gets, nod, adec, swiss, unit

Celgene's Revlimid gets nod from ADEC

Article | 19 November 2007

Print This

The Swiss unit of US drugmaker Celgene says that its oral cancer drug Revlimid (lenalidomide) has received a recommendation for ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in